In today’s fast-paced healthcare landscape, efficiency and accuracy are essential in overcoming workload challenges. Pathology laboratories are under pressure to keep up with growing demands, all while ensuring standardised, consistent and high-quality results.
New research reveals that self-generated electrical activity of small cell lung cancer (SCLC) directly promotes tumor metastasis and progression. This may provide new avenues for future treatments.
For patients, a liquid biopsy which checks for circulating tumour DNA of colon cancer, resembles a standard blood test. However, the method helps avoid chemotherapy for many, a new study finds.
There is no known cure for Alzheimer’s disease (AD), although prescription drug-based treatments that can slow AD progression in some patients are starting to enter clinical use. Biomarkers, quantifiable characteristics of biological processes or pathological conditions of the body, are making it possible to help identify and measure the presence and extent of AD and its degenerative…
Blood-based biomarker (BBB) tests may represent the best weapon to combat the soaring rates of Alzheimer’s disease (AD) throughout the world. Existing clinically validated tests are currently deployed to facilitate diagnosis, to monitor disease and effectiveness of treatments, to quantify progression, and to determine if a patient is appropriate for treatment or participation in a clinical…
Researchers developed an advanced AI tool for automatic analysis of colorectal cancer tissue slides. The new model outperformed all predecessors in the classification of tissue microscopy samples.
New research highlights the potential of circulating tumor DNA (ctDNA) analysis as a non-invasive method to identify actionable biomarkers for breast cancer, enabling individualized therapies.
Traumatic brain injury (TBI) increases dementia risk, but the reasons are poorly understood. Now, a study explores the role of the brain's blood vessels as drivers of Alzheimer's disease.
Helping the brain repair itself after a stroke: A new study based on unique tissue samples from Denmark's Brain Bank may pave the way for new treatments that support brain regeneration.
Liverpool physicists have developed a “diagnostic infrared wand” to more accurately predict the prognosis of oral cancer lesions than current H&E staining techniques.
Complex diseases could require complex biomarkers for accurate diagnosis in the years ahead, according to a leading pathologist. In a keynote address to the 36th European Congress of Pathology in Florence, Italy, Professor Manuel Salto-Tellez highlighted this as one of the major future challenges for the discipline. However, he also believes pathologists will sit at the core of modern medicine.
Metabolic-associated fatty liver disease has 2 types – a liver-specific type and a systemic type that affects other organs and tissues. This discovery could lead to better diagnosis and treatments.
Sakura Finetek Europe and MEDIPATH, a group of independent French pathologists, announced their collaboration to enhance cancer diagnostics and thus contribute to improved patient therapeutic management. This decision is part of an ongoing commitment to improving the quality of care provided to patients and in response to the significant increase in cancer cases over the last years.
A new study shows how inherent variations in a cancer cell and its interactions with its surroundings mould its migration. The findings provide valuable insights into the processes behind metastasis.
Molecular pathology should become centralised in fewer labs to improve efficiencies and affordability, according to leading European experts.
In many cases, metastatic breast cancer is still incurable. To improve the odds, researchers have now analyzed the diversity of metastatic cells and their interactions with their cellular environment.
By combining mass spectrometry and mass cytometry imaging techniques, researchers can now dive deeper into tumors and map the metabolism of individual cells in tumor tissue.
Sakura Finetek’s Tissue-Tek Xpress® x120 Rapid Tissue Processor is the only instrument on the market that allows for continuous, rapid processing of both biopsy and larger tissue, resulting in a streamlined histology workflow. Being part of Sakura’s SMART Automation concept, this tissue processing solution is designed to automate manual work and create a continuous flow throughout the lab.
Testing from histopathology laboratories is considered the gold standard for many diseases. To avoid errors that can significantly impact patient outcomes, an expert details on quality assurance (QA).
